Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2014 Jul 29;99(3):297–304. doi: 10.1136/bjophthalmol-2014-305041

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions

This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 3.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/3.0/

PMC Copyright notice

Timing of treatment initiation, interruption, retreatment and treatment termination with ranibizumab in retinal vein occlusion. (A) Monthly treatment is initiated and continued until maximum VA is achieved (‘maximum VA’ defined as: VA stable for three consecutive monthly assessments while on ranibizumab treatment). (B) Treatment is resumed when loss of VA is observed during monthly monitoring (monthly injections should be administered until VA is again stable for three consecutive monthly assessments while on ranibizumab treatment). (C) If no improvement in VA is observed over a course of three injections, continued treatment with ranibizumab is not recommended. BCVA, best-corrected visual acuity; VA, visual acuity.